FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [ 05-15-2015 ]The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of […]Read More